title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease,20230118T120000,https://www.globenewswire.com/news-release/2023/01/18/2590776/0/en/AC-Immune-Partner-Life-Molecular-Imaging-Initiates-Phase-3-Study-of-Tau-PET-Diagnostic-PI-2620-for-Alzheimer-s-Disease.html,LTGHF,0.032602,Neutral,0.118925
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease - AC Immune  ( NASDAQ:ACIU ) ,20220926T113000,https://www.benzinga.com/pressreleases/22/09/g29005806/ac-immune-partner-lmi-progresses-tau-pet-tracer-pi-2620-into-late-stage-development-in-alzheimers-,LTGHF,0.031241,Neutral,0.108443
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed,20240805T113000,https://www.globenewswire.com/news-release/2024/08/05/2924191/0/en/FDA-Review-of-PsiGAD2-IND-complete-clinical-trial-for-Psilocybin-Assisted-Psychotherapy-in-Patients-with-Generalised-Anxiety-Disorder-to-Proceed.html,LTGHF,0.040011,Neutral,0.028417
